SOL686

SOL686 is a novel small molecule allosteric inhibitor of polo-like kinase 1 (PLK1), developed for the treatment of glioma and potentially other cancers. Unlike traditional PLK1 inhibitors that target the enzyme's active site and are often associated with toxicity, SOL686 specifically targets the Polo-box domain (PBD) of PLK1. This allosteric mechanism aims to reduce adverse events while effectively inhibiting mitotic processes crucial for cancer cell proliferation. The drug originated from research at the University of Cambridge in Prof Ashok Venkitaraman’s laboratory, with further development by PhoreMost and Sentinel Oncology. As of 2025, it remains in preclinical development[2][3][4][5][6][7].

Other names

SOL 686SOL686SOL-686